Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study.

被引：0
|
作者：
Chan, S
Romieu, G
Huober, J
Delozier, T
Tubiana-Hulin, M
Lluch, A
Schneeweiss, A
Llombart, A
Carrasco, E
Fumoleau, P
机构：
[1] City Hosp Nottingham, Nottingham, England
[2] Ctr Val Aurelle, Montpellier, France
[3] Univ Tubingen, Tubingen, Germany
[4] Ctr Francois Baclesse, F-14021 Caen, France
[5] Ctr Rene Huguenin, St Cloud, France
[6] Hosp Clin Univ, Valencia, Spain
[7] Univ Heidelberg, Heidelberg, Germany
[8] Inst Valencia Oncol, Valencia, Spain
[9] Eli Lilly & Co, Alcobendas, Spain
[10] Ctr Georges Francois Leclerc, Dijon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：24S / 24S
页数：1
相关论文
共 50 条
  • [21] A phase IB study of Tarceva™ (erlotinib) plus capecitabine and docetaxel in metastatic breast cancer (MBC).
    Trigo, J
    Baselga, J
    De Rosa, F
    Brennscheidt, U
    Rakhit, A
    Fettner, S
    Jones, R
    Wright, T
    Twelves, C
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6087S - 6087S
  • [22] Docetaxel/gemcitabine: Salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer
    Georgoulias, VA
    ONCOLOGY-NEW YORK, 2001, 15 (02): : 18 - 24
  • [23] Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase Ill study (J021095)
    Sato, N.
    Yamamoto, D.
    Rai, Y.
    Iwase, H.
    Saito, M.
    Iwata, H.
    Masuda, N.
    Oura, S.
    Watanabe, J.
    Kuroi, K.
    CANCER RESEARCH, 2012, 72
  • [24] Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)
    Antoaneta Tomova
    Rupert Bartsch
    Thomas Brodowicz
    Valentina Tzekova
    Constanta Timcheva
    Christoph Wiltschke
    Dany Abi Gerges
    Jan Pawlega
    Stanislav Spanik
    Moshe Inbar
    Christoph C. Zielinski
    Breast Cancer Research and Treatment, 2010, 119 : 169 - 176
  • [25] Capecitabine plus docetaxel combination therapy -: Cost-effectiveness in patients with anthracycline-pretreated advanced breast carcinoma
    Verma, S
    Maraninchi, D
    O'Shaughnessy, J
    Jamieson, C
    Jones, S
    Martín, M
    McKendrick, J
    Miles, D
    Twelves, C
    Hornberger, J
    CANCER, 2005, 103 (12) : 2455 - 2465
  • [26] Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients -: A phase II study
    Ferraresi, V
    Milella, M
    Vaccaro, A
    D'Ottavio, AM
    Papaldo, P
    Nisticò, C
    Thorel, MF
    Marsella, A
    Carpino, A
    Giannarelli, D
    Terzoli, E
    Cognetti, F
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (02): : 132 - 139
  • [27] A phase I dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer
    Slee, PHTJ
    Rodenburg, CJ
    Nortier, JWR
    van Bochove, A
    NETHERLANDS JOURNAL OF MEDICINE, 2004, 62 (09): : 314 - 319
  • [28] Gemcitabine plus epirubicin plus taxol (GET) in metastatic breast cancer (MBC) patients (pts): A multicenter phase II study.
    Donati, S
    Gennari, A
    Conte, PF
    Cetto, GL
    Molino, A
    Crino, L
    Mazzoni, F
    Galligioni, E
    Mansutti, M
    ANNALS OF ONCOLOGY, 2000, 11 : 50 - 50
  • [29] Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial
    Daigo Yamamoto
    Nobuaki Sato
    Yoshiaki Rai
    Yutaka Yamamoto
    Mitsue Saito
    Hiroji Iwata
    Norikazu Masuda
    Shoji Oura
    Junichiro Watanabe
    Satoshi Hattori
    Yoshimasa Matsuura
    Katsumasa Kuroi
    Breast Cancer Research and Treatment, 2017, 161 : 473 - 482
  • [30] Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial
    Yamamoto, Daigo
    Sato, Nobuaki
    Rai, Yoshiaki
    Yamamoto, Yutaka
    Saito, Mitsue
    Iwata, Hiroji
    Masuda, Norikazu
    Oura, Shoji
    Watanabe, Junichiro
    Hattori, Satoshi
    Matsuura, Yoshimasa
    Kuroi, Katsumasa
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (03) : 473 - 482
12345